## Amendments to the Claims

This Listing of Claims will replace all prior versions, and listings, of claims in the application.

## Listing of Claims:

1. (Currently Amended) A compound of formula I



(I)

wherein

X is $=CR^0-$ or =N-;

each of $R^0$, $R^1$, $R^2$, $R^3$ and $R^4$ independently is hydrogen; hydroxy; $C_1$-$C_8$alkyl; $C_2$-$C_8$alkenyl; $C_3$-$C_8$cycloalkyl; $C_3$-$C_8$cycloalkyl-$C_1$-$C_8$alkyl; hydroxy$C_1$-$C_8$alkyl; $C_1$-$C_8$alkoxy$C_1$-$C_8$alkyl; hydroxy$C_1$-$C_8$alkoxy$C_1$-$C_8$alkyl; aryl$C_1$-$C_8$alkyl which optionally may be substituted on the ring by hydroxy, $C_1$-$C_8$alkoxy, carboxy or $C_1$-$C_8$alkoxycarbonyl;

or $R^3$ and $R^4$ form together with the nitrogen and carbon atoms to which they are attached a 5 to 10 membered heterocyclic ring and ~~comprising additionally~~ having 1, 2 or 3 heteroatoms selected from N, O and S;

or each of $R^1$, $R^2$ and $R^3$, independently, is halogen; halo-$C_1$-$C_8$alkyl; $C_1$-$C_8$alkoxy; halo-$C_1$-$C_8$alkoxy; hydroxy$C_1$-$C_8$alkoxy; $C_1$-$C_8$alkoxy$C_1$-$C_8$alkoxy; aryl; aryl$C_1$-$C_8$alkoxy; heteroaryl; heteroaryl-$C_1$-$C_4$alkyl; 5 to 10 membered heterocyclic ring; nitro; carboxy; $C_2$-$C_8$alkoxycarbonyl; $C_2$-$C_8$alkylcarbonyl; -N($C_1$-$C_8$alkyl)C(O) $C_1$-$C_8$alkyl; -N($R^{10}$)$R^{11}$; -CON($R^{10}$)$R^{11}$; -$SO_2$N($R^{10}$)$R^{11}$; or -$C_1$-$C_4$-alkylene-$SO_2$N($R^{10}$)$R^{11}$; wherein each of $R^{10}$ and $R^{11}$ independently is hydrogen; hydroxy; $C_1$-$C_8$alkyl; $C_2$-$C_8$alkenyl; $C_3$-$C_8$cycloalkyl; $C_3$-$C_8$cycloalkyl-$C_1$-$C_8$alkyl; $C_1$-$C_8$alkoxy$C_1$-$C_8$alkyl; hydroxy$C_1$-$C_8$alkoxy$C_1$-$C_6$alkyl; hydroxy$C_1$-$C_8$alkyl; ($C_1$-$C_8$alkyl)-carbonyl; aryl$C_1$-$C_8$alkyl which optionally may be substituted on the ring by hydroxy, $C_1$-$C_8$alkoxy, carboxy or $C_2$-$C_8$alkoxycarbonyl; or 5 to 10 membered heterocyclic ring;

or $R^1$ and $R^2$ form together with the C-atoms to which they are attached aryl or a 5 to 10 membered heteroaryl ~~residue~~ group ~~comprising~~ having one or two heteroatoms selected from N, O and S; or

each of $R^5$ and $R^6$ independently is hydrogen; halogen; cyano; $C_1$-$C_8$alkyl; halo-$C_1$-$C_8$alkyl; $C_2$-$C_8$alkenyl; $C_2$-$C_8$alkynyl; $C_3$-$C_8$cycloalkyl; $C_3$-$C_8$cycloalkyl$C_1$-$C_8$alkyl; $C_5$-$C_{10}$aryl$C_1$-$C_8$alkyl;

each of $R^7$, $R^8$ and $R^9$ is independently hydrogen; hydroxy; $C_1$-$C_8$alkyl; $C_2$-$C_8$alkenyl;

halo-$C_1$-$C_8$alkyl; $C_1$-$C_8$alkoxy; $C_3$-$C_8$cycloalkyl; $C_3$-$C_8$cycloalkyl$C_1$-$C_8$alkyl; aryl$C_1$-$C_8$alkyl; -Y-$R^{12}$ wherein Y is a direct bond or O and $R^{12}$ is a substituted or unsubstituted 5, 6 or 7 membered heterocyclic ring ~~comprising~~ having 1, 2 or 3 heteroatoms selected from N, O and S; carboxy; ($C_1$-$C_8$alkoxy)-carbonyl; -N($C_{1-8}$alkyl)-CO-$NR^{10}R^{11}$; -$CONR^{10}R^{11}$; -$N(R^{10})(R^{11})$; -$SO_2N(R^{10})R^{11}$; $R^7$ and $R^8$ or $R^8$ and $R^9$, respectively form together with the carbon atoms to which they are attached, a 5 or 6 membered heteroaryl ~~comprising~~ having 1, 2 or 3 heteroatoms selected from N, O and S; or a 5 or 6 membered carbocyclic ring;

provided that one of $R^1$, $R^2$ or $R^3$ is -$CON(R^{10})R^{11}$ or-$SO_2N(R^{10})R^{11}$;

in free form or salt form[[.]],

wherein

aryl represents phenyl, naphthyl or 1,2,3,4-tetrahydronaphthyl,

heteroaryl is a 5 or 6 membered aromatic heterocyclic ring, optionally condensed to 1 or 2 benzene rings and/or to a further heterocylic ring, and

wherein a heterocyclic ring is a 5 or 6 membered heterocyclic ring being saturated or unsaturated and optionally condensed to 1 or 2 benzene rings and/or to a further heterocyclic ring.

2. (Original) A process for the production of a compound of formula I according to claim 1, comprising the steps of reacting a compound of formula II



(II)

wherein $R^1$, $R^2$, $R^3$, $R^4$, $R^5$, $R^6$ and X are as defined in claim 1, and Y is a leaving group; with a compound of formula III



(III)

wherein $R^7$, $R^8$ and $R^9$ are as defined in claim 1;

and recovering the resulting compound of formula I in free form or in salt form, and, where required, converting the compound of formula I obtained in free form into the desired salt form, or vice versa.

3. (Cancelled)

4. (Original) A pharmaceutical composition comprising a compound of formula I according to claim 1 or a pharmaceutically acceptable salt thereof, together with one or more pharmaceutically acceptable carriers or diluents therefor.

5. (Cancelled)

6. (Cancelled)

7. (Currently Amended) A combination which comprises (a) a therapeutically effective amount of ~~a ZAP-70, FAK and/or Syk inhibitor~~ the compound of claim 1; and (b) a second drug substance.

8. (Currently Amended) A method for treating ~~or preventing a disease or condition in which ZAP-70, FAK and/or Syk tyrosine inhibitor activation plays a role or is implicated~~ acute or chronic rejection of organ or tissue, atheriosclerosis, vascular occlusion, restenosis, hypertension, heart failure, chronic obstructive pulmonary disease, CNS disease, cancer, infectious disease, inflammatory disease, or autoimmune disease, in a subject in need of such treatment, which comprises administering to such subject a therapeutically effective amount of a compound of formula I according to claim 1 or a pharmaceutically acceptable salt thereof.

9. (Currently Amended) A method for treating ~~or preventing a disease or condition in which ZAP-70, FAK and/or Syk tyrosine inhibitor activation plays a role or is implicated~~ acute or chronic rejection of organ or tissue, atheriosclerosis, vascular occlusion, restenosis, hypertension, heart failure, chronic obstructive pulmonary disease, CNS disease, cancer, infectious disease, inflammatory disease, or autoimmune disease, in a subject in need of such treatment, which comprises administering to such subject a therapeutically effective amount of ~~a ZAP-70, FAK and/or Syk inhibitor~~ the compound of claim 1 in combination with a second drug substance.